F-star Therapeutics (F-star Therapeutics) Total Assets : $83.72 Mil (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is F-star Therapeutics Total Assets?

F-star Therapeutics's Total Assets for the quarter that ended in Sep. 2022 was $83.72 Mil.

During the past 12 months, F-star Therapeutics's average Total Assets Growth Rate was 10.10% per year.

Total Assets is connected with ROA %. F-star Therapeutics's annualized ROA % for the quarter that ended in Sep. 2022 was -79.87%. Total Assets is also linked to Revenue through Asset Turnover. F-star Therapeutics's Asset Turnover for the quarter that ended in Sep. 2022 was 0.01.

F-star Therapeutics Total Assets Historical Data

The historical data trend for F-star Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

F-star Therapeutics Total Assets Chart

F-star Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Total Assets

38.48

63.61

123.02

F-star Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Total Assets	Get a 7-Day Free Trial							114.80	123.02	114.71	100.64	83.72

F-star Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

F-star Therapeutics's Total Assets for the fiscal year that ended in Dec. 2021 is calculated as

Total Assets	=	Total Equity (A: Dec. 2021 )	+	Total Liabilities (A: Dec. 2021 )
	=	96.857	+	26.164
	=	123.02

F-star Therapeutics's Total Assets for the quarter that ended in Sep. 2022 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2022 )	+	Total Liabilities (Q: Sep. 2022 )
	=	56.938	+	26.779
	=	83.72

F-star Therapeutics (NAS:FSTX) Total Assets Explanation

Total Assets is connected with ROA %.

F-star Therapeutics's annualized ROA % for the quarter that ended in Sep. 2022 is

ROA %	=	Net Income (Q: Sep. 2022 )	/	( (Total Assets (Q: Jun. 2022 )	+	Total Assets (Q: Sep. 2022 ))	/ count )
	=	-73.628	/	( (100.644	+	83.717)	/ 2 )
	=	-73.628	/	92.1805
	=	-79.87 %

Note: The Net Income data used here is four times the quarterly (Sep. 2022) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

F-star Therapeutics's Asset Turnover for the quarter that ended in Sep. 2022 is

	Asset Turnover
=	Revenue (Q: Sep. 2022 )	/	( (Total Assets (Q: Jun. 2022 )	+	Total Assets (Q: Sep. 2022 ))	/ count )
=	1.125	/	( (100.644	+	83.717)	/ 2 )
=	1.125	/	92.1805
=	0.01

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

F-star Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of F-star Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

F-star Therapeutics (F-star Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » F-star Therapeutics Inc (NAS:FSTX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Babraham Research Campus, Eddeva B920, Cambridge, GBR, CB22 3AT

Website

https://www.f-star.com

F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.

Executives

Geoffrey Race	director	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Edward Jr Benz	director	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Darlene M Deptula-hicks	officer: See Remarks	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Eliot Forster	director, officer: PRESIDENT AND CEO	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Nessan Bermingham	director	890 WINTER STREET, WALTHAM MA 02451
Louis Kayitalire	officer: CHIEF MEDICAL OFFICER	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Neil Brewis	officer: CHIEF SCIENTIFIC OFFICER	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pamela M. Klein	director	35 PARKWOOD DRIVE, SUITE 210, HOPKINTON MA 01748
Krol Patrick Johan Hendrik	director	GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Garrett Winslow	officer: General Counsel and Secretary	35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Lori Firmani	officer: VP of Finance and Treasurer	35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTCALS, INC., HOPKINTON MA 01748
Scott Andrew Smith	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Timothy P Clackson	director	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christiana Bardon	director, 10 percent owner	86 SOUTH STREET, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Mpm Oncology Impact Management Lp	10 percent owner	399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116